Nephrology

Learn how EGF and UMOD levels may predict diabetic kidney disease progression, offering new tools for clinical risk assessment.

New research uncovers a potential kidney origin for Parkinson’s disease, challenging the idea that it begins in the brain and revealing a new disease pathway.

Presented at ERA 2025, this multicentre study identifies three immune subtypes of checkpoint inhibitor–induced nephritis, linking them to clinical outcomes and treatment responses.

A post-hoc analysis of the CANVAS trial reveals a dose-dependent cardiovascular benefit with canagliflozin in type 2 diabetes, while kidney protection appears consistent across doses.

Pegcetacoplan demonstrated a significant reduction in proteinuria and signs of kidney damage in patients with C3G or IC-MPGN and nephrotic-range proteinuria, according to VALIANT Phase 3 results.

In a landmark trial, IVIG therapy was shown to slow kidney function decline and tissue damage in patients with chronic active antibody-mediated rejection.

Selected as a top 10 abstract at the ERA Congress, this study unveils a new multiple biomarker model to predict tubulointerstitial fibrosis in IgA nephropathy without a biopsy.

Offspring of mothers who experienced preeclampsia during term pregnancies face higher long-term risks of kidney disease, according to a nationwide Danish study.